Business
Positive results of ANCHOR trials of depemokimab
Positive results of ANCHOR trials of depemokimab.
About this update from Gsk Plc
[{"type":"text","content":"\n\nIssued: 14 October 2024, London UK\n \nGSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps\n \n· Primary endpoints met with statistically significant reduction in nasal polyp size and nasal obstruction versus placebo plus standard of care, at 52 weeks\n· Depemokimab is an ultra-long-acting biologic administered once every six months\n· Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) experience a range of symptoms which are widely underestimated and often sub-optimally treated\n \n \n\nGSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with CRSwNP. Both trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score at 52 weeks and change from baseline in mean nasal obstruction score from weeks 49 to 52. The overall incidence and severity of treatment-emergent adverse events across both trials were similar in patients treated with either depemokimab or placebo. Further analysis of these data is ongoing. The full results of ANCHOR-1 and ANCHOR-2 will be presented at an upcoming scientific congress.\n \nKaivan Khavandi, SVP, Global Head of Respiratory/Immunology R&D at GSK, said: \"Globally millions of people suffer from uncontrolled CRSwNP, the majority of whom will exhibit markers of type 2 inflammation. These patients have high corticosteroid exposure and often experience recurrence of nasal polyps following surgery. We're very encouraged by the results from the ANCHOR studies, which demonstrate the potential for depemokimab to offer targeted and sustained suppression of a key inflammatory pathway underlying nasal polyp growth and nasal obstruction. Today's data, along with recent phase III data in severe asthma, will be used in regulatory filings around the world.\"\nDepemokimab is the first ultra-long-acting biologic to be evaluated in phase III trials with an extended half-life and high binding affinity and potency for interleukin-5 (IL-5), which could enable dosing once every six-months for patients with CRSwNP.1-3 IL-5 is present at high levels in nasal polyp tissue and is a key cytokine (protein) in...